The more recent goal in CML treatment is to induce a durable deep molecular response (DMR; BCR-ABL1 ≤ 0.01%) as a prelude to successful treatment-free remission (TFR), which occurs in approximately half of all CML patients who cease TKI therapy (5, 6). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.